David Langleben
Overview
Explore the profile of David Langleben including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
3886
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Langleben D, Lesenko L, Fox B, Eintracht S, Foulkes W, Rosenblatt D
Chest
. 2025 Feb;
167(2):e37-e39.
PMID: 39939060
Pulmonary arterial hypertension (PAH) frequently is associated with an imbalance in antiproliferative bone morphogenic protein-2 receptor signaling and proproliferative type-II activin receptor signaling, favoring the latter. Sotatercept is an activin...
2.
Hoeper M, Rosenkranz S, Badesch D, Humbert M, Langleben D, McConnell J, et al.
Respir Med
. 2024 Dec;
236:107910.
PMID: 39667586
Background: Risk stratification is an essential part of evaluating disease severity in patients with pulmonary arterial hypertension (PAH). This study applied the 4-strata COMPERA 2.0 risk model to the Phase...
3.
Vassiliou A, Roumpaki A, Keskinidou C, Athanasiou N, Tsipilis S, Jahaj E, et al.
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39408968
Endothelin-1 (ET-1) is a potent vasoconstrictor produced by endothelial cells and cleared from circulating blood mainly in the pulmonary vasculature. In a healthy pulmonary circulation, the rate of local production...
4.
Sitbon O, Skride A, Feldman J, Sahay S, Shlobin O, McLaughlin V, et al.
Lancet Respir Med
. 2024 Sep;
12(11):865-876.
PMID: 39307144
Background: The role of serotonin in pulmonary arterial hypertension has been extensively studied in recent decades, with preclinical data strongly indicating involvement in disease pathogenesis; however, clinical studies have yielded...
5.
Rosenkranz S, Ghofrani H, Hoeper M, Langleben D, Hegab S, Rahner C, et al.
J Heart Lung Transplant
. 2024 Sep;
44(2):135-146.
PMID: 39236972
Background: There is limited evidence to support treatment recommendations in patients with pulmonary arterial hypertension (PAH) and comorbidities. To investigate the impact of riociguat treatment in this patient population, we...
6.
Preston I, Howard L, Langleben D, Lichtblau M, Pulido T, Souza R, et al.
Eur Respir J
. 2024 Aug;
64(4).
PMID: 39209477
Care of pulmonary hypertension (PH) patients in special situations requires insightful knowledge of the pathophysiology of the cardiopulmonary system and close interaction with different specialists, depending on the situation. The...
7.
Lotsios N, Keskinidou C, Dimopoulou I, Kotanidou A, Langleben D, Orfanos S, et al.
Int J Mol Sci
. 2024 Aug;
25(15).
PMID: 39125626
Pulmonary arterial hypertension (PAH) is a chronic disease characterized by a progressive increase in mean pulmonary arterial pressure. Mutations in the and genes have been described in familial PAH. The...
8.
Benza R, Simonneau G, Ghofrani H, Corris P, Langleben D, Rosenkranz S, et al.
J Heart Lung Transplant
. 2024 Jun;
43(10):1756-1760.
PMID: 38852934
In Riociguat rEplacing PDE5i therapy evaLuated Against Continued PDE5i thErapy (REPLACE) (NCT02891850), improvements in risk status were observed in patients with pulmonary arterial hypertension (PAH) at intermediate risk switching to...
9.
Benzidia I, Robitaille C, Abualsaud A, McDonald L, Lesenko L, Morin J, et al.
Thromb Res
. 2023 Jul;
229:139-145.
PMID: 37453256
Introduction: Chronic thromboembolic pulmonary hypertension (CTEPH) remains an underdiagnosed disease. Anticoagulation is essential in its therapy to prevent recurrent venous thromboembolism (VTE). According to some international guidelines, vitamin K antagonists...
10.
Benza R, Langleben D, Hemnes A, Vonk Noordegraaf A, Rosenkranz S, Thenappan T, et al.
Eur Respir Rev
. 2022 Oct;
31(166).
PMID: 36198418
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive diseases that can lead to right heart failure and death. Right ventricular dysfunction, hypertrophy and maladaptive remodelling are...